|University of Pennsylvania School of Medicine|
|City: Philadelphia||State: PA|
Summary: University of Pennsylvania School of Medicine has submitted a new policy which improves the institutions already exemplary existing policies with regards to the Speaking domain. Extramural activities (i.e. potential conflicts of interest) are published on a publicly accessible website, personnel are prohibited from participating in speaker’s bureaus, and all presentation content must be controlled by faculty. Better control of continuing education, within a centralized anonymous fund, would be a logical next step for this institution.
Demographics: The major training sites for students are the Hospital of the University of Pennsylvania, the Penn-Presbyterian Medical Center, and the Pennsylvania Hospital. Submitted policies apply to all hospitals and associated clinics.
Updates: This institution did not submit any new or additional policies for the 2012-13 AMSA PharmFree Scorecard. This institution's evaluation was last updated: 10/23/2013.
|Gifts & Meals||Acceptance of gifts and meals is prohibited. Unrestricted educational grants may be used for provision of modest meals for non-CME events.|
|Consulting relationships||Professionals at the School of Medicine may consult on their "1 day in 7" time if the payments received are reasonable for the services provided.|
|Industry-funded speaking relationships||Professionals at the School of Medicine may consult (including providing presentations) on their "1 day in 7" time if the payments received are reasonable for the services provided.|
|Disclosure||The School of Medicine provided no disclosure policy.|
|Pharmaceutical samples||Model samples policy:
"No physical medication samples are allowed within the institution and the institution practices. The distribution of sample medication vouchers in inpatient areas is prohibited."
The School of Medicine also has a detailed policy on its voucher program for indigent medications and starter packs.
|Purchasing & Formularies||Faculty members with financial conflicts of interest are forbidden from serving on purchasing committees.|
|Industry Sales Representatives||The School of Medicine requires pharmaceutical representatives to register once with the institution, and must have an appointment before being permitted on site. In addition, representatives may only meet in non-patient care areas.
"Pharmaceutical company representatives are expected to communicate warnings and contraindications with the same fervor with which they promote indications and endorsements of medical experts."
|On-campus Education||This policy does not stipulate a truly anonymized central fund for unrestricted grants, but it does allow for institutional control/approval of content, and non-CME educational events given by industry must not discuss non-formulary drugs.|
|Attendance at Industry-Sponsored Lectures & Meetings Off-Campus||According to this policy, reimbursement for travel and other funds related to off-site education may only be provided by industry through unrestricted educational grants. Industry may not select the recipient of these grants.|
|Industry Support for Scholarships & Funds for Trainees||Model policy:
"In the case of professionals-in-training or other trainees, conference funds may be donated to a clinical department/division, provided that department faculty (and not the company) chooses the trainee to receive the funds for attending the meeting."
|Medical school curriculum||The curricular materials demonstrate that this institution covers conflict of interest and the effects of pharmaceutical marketing on heath care decision-making by physicians in a thorough, meaningful way.
"With regard to physicians-in-training, departmental curricula will include discussion and reflection on managing encounters with Industry representatives, and house staff should be instructed on how promotional activities may influence judgment in prescribing decisions and research activities."
|Do the policies specify an oversight mechanism?||Various named parties are responsible for the implementation of the guidelines given.|
|Are there explicit sanctions for noncompliance?||Possible sanctions for non-compliance with the guidelines were not provided.|
|Good progress toward model policy|
|No policy, or policy unlikely to have a substantial effect on behavior|
|Did not report|
|Policy not relevant to this institution (e.g., does not make purchasing decisions)|